REAL WORLD OUTCOMES OF VEDOLIZUMAB FOR INFLAMMATORY BOWEL DISEASE POST LIVER TRANSPLANTATION

被引：0
|
作者：
Peverelle, Matthew
Mills, Christopher D.
Testro, Adam
De Cruz, Peter
机构：
来源：
GASTROENTEROLOGY | 2018年 / 154卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Mo1901
引用
收藏
页码：S845 / S845
页数：1
相关论文
共 50 条
  • [21] Benefit of measuring vedolizumab concentrations in inflammatory bowel disease patients in a real-world setting
    Kolehmainen, Sara
    Ylisaukko-Oja, Tero
    Jokelainen, Jari
    Koivusalo, Mirkka
    Jokiranta, T. Sakari
    Sipponen, Taina
    [J]. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2021, 56 (08) : 906 - 913
  • [22] Vedolizumab is safe and effective in moderate-to-severe inflammatory bowel disease following liver transplantation
    Wright, Andrew P.
    Fontana, Robert J.
    Stidham, Ryan W.
    [J]. LIVER TRANSPLANTATION, 2017, 23 (07) : 968 - 971
  • [23] REAL-WORLD SAFETY AND EFFICACY OF USTEKINUMAB AND VEDOLIZUMAB IN PEDIATRIC PATIENTS WITH INFLAMMATORY BOWEL DISEASE
    Hsu, Diane
    Lee, Justin
    Kotzen, Alison
    Bensen, Rachel
    Goyal, Alka
    [J]. INFLAMMATORY BOWEL DISEASES, 2024, 30 : S73 - S74
  • [24] REAL-WORLD SAFETY AND EFFICACY OF USTEKINUMAB AND VEDOLIZUMAB IN PEDIATRIC PATIENTS WITH INFLAMMATORY BOWEL DISEASE
    Anjur, Kavya
    Neiman, Nicole
    Kotzen, Alison
    Pond, Stephen
    Goyal, Alka
    [J]. GASTROENTEROLOGY, 2022, 162 (07) : S826 - S826
  • [25] Letter: vedolizumab for autoimmune liver disease associated inflammatory bowel disease
    Pavlidis, P.
    Graham, J.
    Gulati, S.
    Dubois, P.
    Heneghan, M.
    Joshi, D.
    Hayee, B.
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2018, 47 (10) : 1422 - 1423
  • [26] COMPARISON OF REAL-WORLD TREATMENT OUTCOMES WITH INFLIXIMAB VERSUS VEDOLIZUMAB IN BIOLOGIC-NAIVE PATIENTS WITH INFLAMMATORY BOWEL DISEASE
    Latremouille-Viau, Dominick
    Burne, Rebecca
    Shi, Sherry
    Adsul, Shashi
    Patel, Haridarshan
    [J]. GASTROENTEROLOGY, 2019, 156 (06) : S638 - S639
  • [27] Comparison of Real-World Treatment Outcomes With Vedolizumab Versus Infliximab in Biologic-Naive Patients With Inflammatory Bowel Disease
    Patel, Haridarshan
    Latremouille-Viau, Dominick
    Burne, Rebecca
    Shi, Sherry
    Adsul, Shashi
    [J]. CROHNS & COLITIS 360, 2019, 1 (02)
  • [28] PREDICTORS AND OUTCOMES OF VEDOLIZUMAB DOSE ESCALATION IN INFLAMMATORY BOWEL DISEASE
    Levine, Louis
    Gaidos, Jill K.
    Proctor, Deborah D.
    Al Bawardy, Badr
    [J]. GASTROENTEROLOGY, 2021, 160 (06) : S703 - S703
  • [29] VEDOLIZUMAB TROUGH LEVELS AND CLINICAL OUTCOMES IN INFLAMMATORY BOWEL DISEASE
    Guidi, L.
    Pugliese, D.
    Tonucci, T. Panici
    Tolusso, B.
    Felice, C.
    Papa, A.
    Ennas, S.
    Di Mario, C.
    Gasbarrini, A.
    Rapaccini, G. L.
    Armuzzi, A.
    [J]. DIGESTIVE AND LIVER DISEASE, 2018, 50 (02) : E99 - E100
  • [30] Liver transplantation and inflammatory bowel disease
    Papatheodoridis, GV
    Hamilton, M
    Rolles, K
    Burroughs, AK
    [J]. JOURNAL OF HEPATOLOGY, 1998, 28 (06) : 1070 - 1076
12345